S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
NASDAQ:SRRK

Scholar Rock (SRRK) Stock Price, News & Analysis

$13.85
-0.10 (-0.72%)
(As of 04/19/2024 ET)
Today's Range
$13.18
$14.20
50-Day Range
$13.20
$17.76
52-Week Range
$5.56
$21.17
Volume
707,144 shs
Average Volume
645,934 shs
Market Capitalization
$1.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.17

Scholar Rock MarketRank™ Stock Analysis

Analyst Rating
Buy
3.17 Rating Score
Upside/​Downside
81.7% Upside
$25.17 Price Target
Short Interest
Bearish
16.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$351,931 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.01) to ($1.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

114th out of 909 stocks

Biological Products, Except Diagnostic Industry

14th out of 149 stocks

SRRK stock logo

About Scholar Rock Stock (NASDAQ:SRRK)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

SRRK Stock Price History

SRRK Stock News Headlines

SRRK Oct 2024 15.000 put
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
SRRK Oct 2024 20.000 call
SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp (2QK.BE)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Scholar Rock Reports Wider Loss For Full Year
SRRK Apr 2024 10.000 put
SRRK Apr 2024 22.500 call
SRRK Oct 2024 5.000 call
SRRK Jul 2024 10.000 call
SRRK Oct 2024 25.000 call
SRRK Mar 2024 7.500 put
Scholar Rock Holding Corp.
SRRK Mar 2024 15.000 call
SRRK Mar 2024 15.000 put
See More Headlines
Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SRRK
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.17
High Stock Price Target
$30.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+81.7%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Net Income
$-165,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$33.19 million
Book Value
$3.12 per share

Miscellaneous

Free Float
57,465,000
Market Cap
$1.08 billion
Optionable
Optionable
Beta
0.90
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Jay Thomas Backstrom M.D. (Age 69)
    M.P.H., President, CEO & Director
    Comp: $686.49k
  • Mr. Edward H. Myles MBAMr. Edward H. Myles MBA (Age 52)
    CFO, COO & Treasurer
    Comp: $668.49k
  • Ms. Junlin Ho J.D. (Age 45)
    General Counsel & Corporate Secretary
    Comp: $563.73k
  • Mr. Mo Qatanani Ph.D. (Age 50)
    Chief Scientific Officer
  • Rushmie Nofsinger
    Vice President of Corporate Affairs & Investor Relations
  • Ms. Caryn Parlavecchio (Age 52)
    Chief Human Resources Officer
  • Ms. Lisa Amaya Price
    Senior Vice President of Human Resources
  • Ms. Erin Moore (Age 49)
    Senior Vice President of Finance
  • Mr. Ryan Iarrobino
    Senior Vice President of Clinical Development & Operations
  • Dr. Jing L. Marantz M.B.A. (Age 59)
    M.D., Ph.D., Chief Medical Officer

SRRK Stock Analysis - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings
or view top-rated stocks.

What is Scholar Rock's stock price target for 2024?

6 brokers have issued twelve-month price targets for Scholar Rock's stock. Their SRRK share price targets range from $20.00 to $30.00. On average, they predict the company's stock price to reach $25.17 in the next twelve months. This suggests a possible upside of 81.7% from the stock's current price.
View analysts price targets for SRRK
or view top-rated stocks among Wall Street analysts.

How have SRRK shares performed in 2024?

Scholar Rock's stock was trading at $18.80 at the beginning of the year. Since then, SRRK shares have decreased by 26.3% and is now trading at $13.85.
View the best growth stocks for 2024 here
.

When is Scholar Rock's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SRRK earnings forecast
.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) posted its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.01.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

Scholar Rock (SRRK) raised $76 million in an IPO on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRRK) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners